18F-FDG PET/CT作为评估肺结核治疗充分性和预测复发的无创生物标志物
结果显示,无RMA组无复发,RMA组有3例(9%)复发,且所有复发患者均有双侧病变伴空洞。
要点
- 治疗结束时18F-FDG PET/CT无残留代谢活性对结核复发具有保护作用。
- RMA组中约9%的患者在完成治疗后6个月内出现结核复发。
- 复发患者均表现为双侧病变伴肺空洞。
核心结论
- 治疗结束时18F-FDG PET/CT阴性结果对结核复发具有保护作用。
- RMA组中9%的患者在完成抗结核治疗后6个月内可能复发。
- 复发患者中双侧病变伴肺空洞常见。
研究设计与样本
- 患者于治疗结束时接受18F-FDG PET/CT评估RMA,随后随访6个月观察复发。
- 复发通过细菌学检测确认,复发患者重复行18F-FDG PET/CT。
主要发现
- 33例患者存在RMA(RMA组),20例达到完全代谢反应(非RMA组)。
- RMA组肺空洞 prevalence 更高(P = 0.035)。
- 两组在年龄、性别、HIV感染、体重指数或血红蛋白水平方面无显著差异(P > 0.05)。
- 随访期间非RMA组无患者复发,RMA组有3例患者复发。
- 所有复发患者均为双侧病变伴肺空洞。
关键数值与推荐
- RMA组中9%的患者在完成抗结核治疗后6个月内出现复发。
- RMA组肺空洞 prevalence 更高(P = 0.035)。
临床怎么用
- 治疗结束时18F-FDG PET/CT无残留代谢活性可提示复发风险低。
- 存在RMA的患者,尤其伴有双侧病变和肺空洞者,应加强随访监测。
局限性
- 75%患者合并HIV感染,可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Microbial culture is the gold standard for determining the effectiveness of tuberculosis treatment. End-of-treatment (EOT) 18F-FDG PET/CT findings are variable among patients with negative microbial culture results after completing a standard regimen of antituberculous treatment (ATT), with some patients having a complete metabolic response to treatment whereas others have residual metabolic activity (RMA). We herein determine the impact of findings on EOT 18F-FDG PET/CT on tuberculosis relapse in patients treated with a standard regimen of ATT for drug-sensitive pulmonary tuberculosis (DS-PTB). Methods: Patients who completed a standard regimen of ATT for DS-PTB and were declared cured based on a negative clinical and bacteriologic examination were prospectively recruited to undergo EOT 18F-FDG PET/CT. Images were assessed for the presence of RMA. Patients were subsequently followed up for 6 mo looking for symptoms of tuberculosis relapse. When new symptoms developed, relapse was confirmed with bacteriologic testing. Repeat 18F-FDG PET/CT was done in patients who relapsed. Results: Fifty-three patients were included (mean age, 37.81 ± 11.29 y), with 62% being male and 75% HIV-infected. RMA was demonstrated in 33 patients (RMA group), whereas 20 patients had a complete metabolic response to ATT (non-RMA group). There was a higher prevalence of lung cavitation in the RMA group (P = 0.035). The groups did not significantly differ in age, sex, presence of HIV infection, body mass index, or hemoglobin level (P > 0.05). On follow-up, no patients in the non-RMA group developed tuberculosis relapse. Three patients in the RMA group developed relapse. All patients who developed tuberculosis relapse had bilateral disease with lung cavitation. Conclusion: A negative EOT 18F-FDG PET/CT result is protective against tuberculosis relapse. Nine percent of patients with RMA after ATT may experience tuberculosis relapse within 6 mo of completing ATT. Bilateral disease with lung cavitation is prevalent among patients with tuberculosis relapse.
引用
- Lawal IO, Fourie BP, Mathebula M, et al. 18F-FDG PET/CT as a Noninvasive Biomarker for Assessing Adequacy of Treatment and Predicting Relapse in Patients Treated for Pulmonary Tuberculosis. J Nucl Med. 2019. PMID: 31451489. doi:10.2967/jnumed.119.233783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。